Company Overview of Ability Biomedical Corp.
Ability Biomedical Corporation develops chemokine-based therapeutics for treatment of Multiple Sclerosis (MS), as well as acute spinal cord and brain injuries. The company is researching the efficacy of injectable interferon-inducible protein 10 (IP-10) antibody in alleviating and improving symptoms of multiple sclerosis, and eliminating physical deterioration post-spinal cord injury. Ability Biomedical was founded in 2002 and is based in Vancouver, Canada. As of August 2004, Ability Biomedical Corporation was a subsidiary of Medarex Inc. Later, it operates as a subsidiary of Bristol-Myers Squibb Company.
1055 West Georgia Street
Vancouver, BC V6E 3R5
Founded in 2002
Key Executives for Ability Biomedical Corp.
Similar Private Companies By Industry
|1220047 Ontario Limited||Americas|
|1504607 Ontario Inc.||Americas|
|2227929 Ontario Inc.||Americas|
|2ic Systems Inc.||Americas|
|49-97 Capital Partners||Americas|
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.
Most Searched Private Companies
|Company Name||Geographic Region|
|Lawyers Committee for Civil Rights Under Law||United States|
|The Advertising Council, Inc.||United States|
|Tax Management Inc||United States|
|John F. Kennedy Center For The Performing Arts||United States|
|NYC2012, Inc.||United States|
Sponsored Financial Commentaries
Only a company representative may request an update for the company profile. Documentation will be required.
To contact Ability Biomedical Corp., please visit --. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.